STA9090 as a Potential Therapeutic Agent for Liver Fibrosis by Modulating the HSP90/TβRII/Proteasome Interplay: Novel Insights from In Vitro and In Vivo Investigations

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 8; p. 1080
• Main Authors: Mohammed, Osama A, Abdel-Reheim, Mustafa Ahmed, Alamri, Mohannad Mohammad S, Alfaifi, Jaber, Adam, Masoud I. E, Saleh, Lobna A, Farrag, Alshaimaa A, Yahia, Amar Ibrahim Omer, Abdel-Ghany, Sameh, AlQahtani, AbdulElah Al Jarallah, Bahashwan, Emad, Eltahir, Hanan B, Mohammed, Nahid A, El-wakeel, Hend S, Hazem, Sara H, Saber, Sameh
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 28.07.2023; MDPI
• Subjects: Apoptosis; Collagen; Cytokines; Drug therapy; Fibrosis; Heat shock proteins; HSP90; Inflammation; Investigations; Liver diseases; liver fibrosis; Oxidative stress; proteasome; STA9090; TGF-β; Tumor necrosis factor-TNF; TβRII; Egypt
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16081080

Liver fibrosis is a progressive condition characterized by the build-up of fibrous tissue resulting from long-term liver injury. Although there have been advancements in research and treatment, there is still a need for effective antifibrotic medication. HSP90 plays a crucial role in the development of fibrosis. It acts as a molecular chaperone that assists in the proper folding and stability of TβRII, potentially regulating the signaling of TGF-β1. It has been established that TβRII can be degraded through the proteasome degradation system, either via ubiquitination-dependent or -independent pathways. In the present study, STA9090 demonstrated promising effects in both in vitro and in vivo models. It reduced LDH leakage, prolonged the survival rate of hepatocytes in rats with liver fibrosis, and improved liver function. Importantly, STA9090 exerted pleiotropic effects by targeting proteins involved in limiting collagen production, which resulted in improved microscopic features of the rat livers. Our findings suggest that STA9090-induced inhibition of HSP90 leads to the degradation of TβRII, a fibrogenic client protein of HSP90, through the activation of the 20S proteasomal degradation system. We also revealed that this degradation mechanism is not dependent on the autophagy–lysosomal pathway. Additionally, STA9090 was found to destabilize HIF-1α and facilitate its degradation, leading to the reduced transcription of VEGF. Moreover, STA9090’s ability to deactivate the NFκB signaling pathway highlights its potential as an anti-inflammatory and antifibrotic agent. However, further research is necessary to fully elucidate the underlying mechanisms and fully capitalize on the therapeutic benefits of targeting HSP90 and associated pathways.